Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Imre forced to re-negotiate Baxter Healthcare deal:

This article was originally published in Clinica

Executive Summary

Imre has begun re-negotiation of its Prosorba column distribution deal with Baxter Healthcare, following the US FDA's decision in January to block the proposed relabelling of Imre's Prosorba columns (see Clinica No 638, p 19). The FDA ruled that the approved indication for the Prosorba column will remain idiopathic thrombocytopenic purpura rather than be changed to immune thrombocytopenic purpura as requested by Imre in March 1993. In April 1994, Imre entered a ten-year exclusive distribution agreement with Baxter (see Clinica No 609, p 11). The start of the discussions with Baxter has forced Imre to postpone the second round of its previously announced private placement.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT090595

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel